Gilead finally gained FDA approval on Thursday for lenacapavir, its closely-watched capsid inhibitor for HIV-1, the most common type of HIV. Lenacapavir will be marketed in the US as Sunlenca for heavily pretreated HIV-1 patients who are failing their current antiretroviral regimen. The long-acting subcutaneous injection is administered just twice…
...
News Ticker
- [ March 22, 2023 ] Protein Scientist – Axbio, Inc. – Santa Clara, CA San Francisco Biotech Jobs
- [ March 22, 2023 ] The fresh water we take for granted News
- [ March 22, 2023 ] Research Associate I/II or Senior Research Associate I – Tenaya Therapeutics, Inc. – South San Francisco, CA San Francisco Biotech Jobs
- [ March 22, 2023 ] Sr. Scientist II, Process Chemistry – Exelixis, Inc. – Alameda, CA San Francisco Biotech Jobs
- [ March 22, 2023 ] Associate/Technician, Pharmaceutical Manufacturing, Fremont CA-Day Shift – Boehringer Ingelheim – Fremont, CA San Francisco Biotech Jobs
Copyright © 2022 Biotech Networks, LLC
